Narcolepsy type 1 is characterized by excessive daytime sleepiness and cataplexy, as well as hypocretin deficiency. Cataplexy (the loss of voluntary postural muscle tone, often in response to emotional stimuli) is one of the most disabling features and is associated with significant social impairment and risk of injury. Cataplexy is usually alleviated by antidepressants sodium oxybate and pitolisant. In this case report, we describe three patients with severe, drug-resistant cataplexy who experienced a dramatic improvement when treated with tropatepine, an anticholinergic muscarinic antagonist (commonly used to prevent neuroleptic-induced parkinsonism) after the usual treatments had failed. The single side effect was mild mouth dryness. In addition to providing a new therapeutic option for resistant cataplexy, this benefit supports a role of cholinergic muscarinic transmission in rapid eye movement sleep atonia.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020693 | PMC |
| http://dx.doi.org/10.5664/jcsm.9030 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Multidrug resistant narcolepsy].
Rev Neurol
July 2023
Hospital Universitario de Salamanca, Salamanca, España.
Introduction: Narcolepsy type 1 is a focal degenerative disease of the hypothalamus that selectively affects orexin (hypocretin)-producing neurons. It presents multiple clinical manifestations, both in wakefulness and in sleep. The symptoms are often so disruptive that they cause enormous suffering and impair patients' quality of life.
View Article and Find Full Text PDFSuccessful treatment of drug-resistant cataplexy with the anticholinergic drug tropatepine.
J Clin Sleep Med
April 2021
National Reference Center for Narcolepsy, Sleep Disorders Unit, University Hospital Pitié-Salpêtrière, Paris, France.
Narcolepsy type 1 is characterized by excessive daytime sleepiness and cataplexy, as well as hypocretin deficiency. Cataplexy (the loss of voluntary postural muscle tone, often in response to emotional stimuli) is one of the most disabling features and is associated with significant social impairment and risk of injury. Cataplexy is usually alleviated by antidepressants sodium oxybate and pitolisant.
View Article and Find Full Text PDF"I feel my arm shaking": partial cataplexy mistaken for drug-resistant focal epilepsy.
Sleep Med
August 2017
Sleep Disorders Unit, National Reference Center for Narcolepsy, Hypersomnia and Kleine-Levin Syndrome, Pitié-Salpêtrière Hospital, Paris, France.
French consensus. Management of patients with hypersomnia: Which strategy?
Rev Neurol (Paris)
September 2017
Centre de référence nationale narcolepsie et hypersomnie idiopathique, 34295 Montpellier cedex 5, France; Unité des troubles du sommeil et de l'éveil, hôpital Gui-De-Chauliac, 80, avenue Augustin-Fliche, 34295 Montpellier cedex 5, France; Inserm U1061, 34295 Montpellier, France. Electronic address:
Central hypersomnias principally involves type 1 narcolepsy (NT1), type 2 narcolepsy (NT2) and idiopathic hypersomnia (IH). Despite great progress made in understanding the physiopathology of NT1 with low cerebrospinal fluid hypocretin-1 levels, current treatment remains symptomatic. The same applies to NT2 and IH, for which the physiopathology is still largely unknown.
View Article and Find Full Text PDFAttention-Deficit/Hyperactivity Disorder (ADHD) Symptoms in Pediatric Narcolepsy: A Cross-Sectional Study.
Sleep
August 2015
National Reference Centre for Orphan Diseases, Narcolepsy, Idiopathic hypersomnia and Kleine-Levin Syndrome, France.
Study Objectives: To evaluate the frequency, severity, and associations of symptoms of attention-deficit/hyperactivity disorder (ADHD) in children with narcolepsy with and without cataplexy.
Design: Cross-sectional survey.
Settings: Four French national reference centers for narcolepsy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!